All Posts

Januar 22, 2021 Written by Kymberlie McNicholas, Founder of The Way to My Heart “LimFlow recently presented compelling 12-month data from its PROMISE I US feasibility study at the VIVA conference, which demonstrated amputation free survival of 70%, limb salvage of 77%, and survival of 91% at 12 months,” explains LimFlow CEO Dan Rose. As part of our ongoing Vascular Innovation Series in conjunction with The Way to My Heart, Emmy Award-winning Journalist Kym McNicholas intervie

January 7, 2021 A Note from Vascular Cures: While much of the world and our lives have been on hold this year, it is heartening to know that new technologies with the potential to dramatically improve, or even save, the lives of vascular patients have continued to advance. Vascular Cures and The Way to My Heart are particularly excited about certain mission-aligned improvements on the horizon, which is to say those that focus on prevention, patient empowerment, and have a mea

October 23, 2020 Interview by Kym McNicholas, The Way To My Heart As part of our ongoing Vascular Innovation Series in conjunction with The Way To My Heart, journalist Kym McNicholas interviewed DermaFlow CEO and Board Member, Irene Jaffe, Ph.D. DermaFlow develops a non-invasive proprietary technology to monitor and stimulate the peripheral blood flow. Dermiflow’s Perivasc and DermVasc are currently limited to investigative use. U.S. Congressional Representative Donald Payne